Grégory La Sala

Dr. Grégory La Sala

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGrégory La Sala
Grégory La Sala
CMCamille Michiels
Camille Michiels
TKTim Kükenshöner
Tim Kükenshöner
TBTania Brandstoetter
Tania Brandstoetter
BMBarbara Maurer
Barbara Maurer
OHOliver Hantschel
Oliver Hantschel
The transcription factor STAT3 is frequently activated in human solid and hematological malignancies and remains a challenging therapeutic target with no approved drugs to date. Here, we develop synthetic antibody mimetics, termed monobodies, to interfere with STAT3 signaling. These monobodies are highly selective for STAT3 and bind with nanomolar affinity to the N-terminal and coiled-coil domains. Interactome analysis detects no significant binding to other STATs or additional off-target proteins, confirming their exquisite specificity. Intracellular expression of monobodies fused to VHL, an E3 ubiquitin ligase substrate receptor, results in degradation of endogenous STAT3. The crystal structure of STAT3 in complex with monobody MS3-6 reveals bending of the coiled-coil domain, resulting in diminished DNA binding and nuclear translocation. MS3-6 expression strongly inhibits STAT3-dependent transcriptional activation and disrupts STAT3 interaction with the IL-22 receptor. Therefore, our study establishes innovative tools to interfere with STAT3 signaling by different molecular mechanisms.

7 November 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
CCChristina Claus
Christina Claus
CFClaudia Ferrara-Koller
Claudia Ferrara-Koller
JSJohannes Sam
Johannes Sam
SLSabine Lang
Sabine Lang
RARosmarie Albrecht
Rosmarie Albrecht
Christian KleinChristian Klein
Christian Klein
Background/Objectives: T cell bispecific antibodies (TCBs) result in the activation of T cell receptor signaling upon binding to tumor antigens providing signal 1 to T cells. To enhance and sustain their activity, a co-stimulatory signal 2 is required. Here CEACAM5-targeted 4-1BBL antibody fusion proteins for combination with CEA-TCB (cibisatamab, RG7802) are described in an investigation of the relationship between the CEACAM5 epitope and T cell activity. Methods: CEACAM5-targeted bispecific 4-1BBL antibody fusion proteins (CEA-4-1BBLs) were generated based on different CEACAM5 antibodies and characterized in vitro in Jurkat-4-1BB reporter and PBMC cell assays. The impact of shed CEA on in vitro activity and cynomolgus cross-reactivity was studied. In vivo efficacy was assessed in human stem cell humanized NSG mice xenograft models bearing MKN-45 and HPAFII tumors. Results: MFE23-4-1BBL and Sm9b-4-1BBL showed superior functional activity in Jurkat-4-1BB reporter and primary T cell assays when combined with the CD3 antibody V9, whereas T84.66-LCHA-4-1BBL and A5B7-4-1BBL performed better when combined with CEA-TCB. In humanized NSG mice MKN-45 and HPAFII xenograft models, T84.66-LCHA-4-1BBL mediated the best anti-tumor efficacy. Conclusions: For the assessment of the combination of CEA-TCB with CEA-4-1BBL, co-stimulatory antibody fusion protein in vitro assays are not sufficient to fully capture the complex relationships affecting efficacy. Thus, screening with different cell assays and in vivo efficacy studies in combination with CEA-TCB are essential to select the best candidate. Based on the totality of data on the T84.66-LCHA-4-1BBL antibody fusion protein comprising the CEACAM5 antibody, T84.66-LCHA was selected as the optimal combination partner for CEA-TCB.

27 April 2026 in mAbs
Verified
Journal Article
Open access
GSGrégory La Sala
Grégory La Sala
KKKatharina B. Kroell
Katharina B. Kroell
MPMudita Pincha
Mudita Pincha
CGChristian Gassner
Christian Gassner
LDLorenzo Deho
Lorenzo Deho
AVAnna Vangone
Anna Vangone
The development of anti-CD3 antibody-based T cell engager therapeutics has improved the treatment of various malignancies, yet the challenge of achieving tumor-specific targeting while minimizing on-target off-tumor effects in normal tissues remains a substantial hurdle. One promising strategy to address this issue involves engineering antibodies with conditional pH-dependent binding affinities, capitalizing on the acidic microenvironment characteristics of tumors (pH ~ 6.5-6.8) compared to the neutral pH of healthy tissues (pH ~ 7.4). In this study, we focus on the pH-engineering of antibody binders against the human CD3 antigen, a critical component of T cell activation, to achieve preferential binding at acidic pH. Using molecular dynamics (MD) simulations on the reported CD3ɛ antibody binder 40G5c, we shed light on possible molecular mechanisms of the pH-responsiveness of key mutations and their impact on the overall binder structure at physiological or acidic pH. Our study highlights how MD has emerged as a powerful tool to guide and explain intrinsic pH-dependent molecular mechanisms in antibody engineering. Lastly, we report that our engineered CD3 binders preferentially bind and activate T cells under acidic pH conditions and display favorable affinity and pH-window profiles.

30 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CCChristina Claus
Christina Claus
CFClaudia Ferrara-Koller
Claudia Ferrara-Koller
JSJohannes Sam
Johannes Sam
SLSabine Lang
Sabine Lang
RARosmarie Albrecht
Rosmarie Albrecht
Christian KleinChristian Klein
Christian Klein
Background/Objectives: T cell bispecific antibodies (TCBs) result in the activation of T cell receptor signaling upon binding to tumor antigens providing signal 1 to T cells. To enhance and sustain their activity a co-stimulatory signal 2 is required. Here CEACAM5-targeted 4-1BBL antibody fusion proteins for combination with CEA-TCB (cibisatamab, RG7802) are described to investigate the relationship of CEACAM5 epitope and activity. Methods: CEACAM5-targeted bispecific 4-1BBL antibody fusion proteins (CEA-4-1BBL) were generated based on different CEACAM5 antibodies and characterized in vitro in Jurkat-4-1BB reporter and PBMC cell assays. The impact of shed CEA on in vitro activity and cynomolgus cross-reactivity was studied. In vivo efficacy was assessed in human stem cell humanized NSG mice xenograft models bearing MKN-45 and HPAFII tumors. Results: MFE23-4-1BBL and Sm9b-4-1BBL showed superior functional activity in Jurkat-4-1BB reporter and in primary T cell assays when combined with the CD3 antibody V9, whereas T84.66-LCHA-4-1BBL and A5B7-4-1BBL performed better when combined with CEA-TCB. In humanized NSG mice MKN-45 and HPAFII xenograft models T84.66-LCHA-4-1BBL mediated the best anti-tumor efficacy. Conclusions: For the assessment of the combination of CEA-TCB with CEA-4-1BBL co-stimulatory antibody fusion proteins in vitro assays are not sufficient to fully capture the complex relationships affecting efficacy. Thus, screening with different cell assays and in vivo efficacy studies in combination with CEA-TCB is essential to select the best candidate. Based on the totality of data the T84.66-LCHA-4-1BBL antibody fusion protein comprising the CEACAM5 antibody T84.66-LCHA was selected as optimal combination partner for CEA-TCB.